Risk factor
Poor trading liquidity
Profitability factor
Very weak growth
About
Mercuries & Associates Holding, Ltd. operates as an investment holding company with diverse business interests spanning life insurance, retail of everyday commodities and food, pharmaceuticals, and information technology services. Its insurance division provides a comprehensive suite of products, encompassing various life coverage options (lifetime, whole life, variable), health policies (hospitalization, medical, cancer, long-term care, disability), and accident protection (personal, travel, group). Additionally, it offers annuity plans (immediate, deferred, variable) and foreign currency pension products. The retail segment is involved in the procurement and sale of a broad spectrum of goods, ranging from everyday necessities, groceries, alcoholic beverages, and tobacco to fresh produce, medical supplies, infant products, cosmetics, and beauty items. This division also markets branded footwear, apparel, and accessories, alongside operating fast-food establishments serving items like noodles, rice dishes, fried pork chops, Japanese bento sets, and pizzas. Furthermore, it handles the sale and interior decoration of home furnishings, including furniture, cabinets, kitchen equipment, and mattresses. Within its pharmaceutical operations, Mercuries & Associates Holding manufactures active pharmaceutical ingredients (APIs) such as valproic acid and allopurinol. It also produces API intermediates, including diethyl dipropyl malonate and PENT-2 ethyl 2-allyl-2-cyano-3-methylhexanoate, along with specialty chemicals like diethyl ketone. Moreover, the company delivers information technology services, specializing in the planning, development, and implementation of software and hardware solutions for financial systems and public utilities, complemented by ongoing maintenance support. Founded in Taipei, Taiwan, in 1965, the company officially changed its name from Mercuries & Associates, Ltd. to Mercuries & Associates Holding, Ltd. in January 2015.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is overpriced on P/E, undervalued on